Opsonin Group

What Opsonin Group does

Opsonin Group is identified by the website domain "opsonin-pharma.com," which indicates a pharmaceutical-sector entity, but the provided source data does not specify functional scope, product portfolio, therapeutic segments, manufacturing footprint, or target markets. The dataset contains no populated fields for products, services, technology, customer segments, pricing, distribution channels, management team, subsidiaries, funding history, or geographic operations. Accordingly, this description is grounded strictly in the inferred sector (pharmaceuticals) and the explicit data gaps noted across the input.

Beyond the sector inference, no business-model mechanics are disclosed. There is no information on revenue model (whether branded generics, APIs, contract manufacturing, distribution, or branded originator drugs), pricing structure, go-to-market motion, sales channels, or customer segmentation. No core technology, proprietary features, integrations, or digital/AI capabilities are documented. The company's operating status, founding date, legal name, ownership structure, and headcount are also unrecorded in the source. As a result, any further characterization of what Opsonin Group builds, sells, or serves would be unsupported and is intentionally omitted; investment-relevant claims should be deferred until foundational company metadata is sourced.

Name

Opsonin Group

Website

https://opsonin.com

Company type

Private

Headcount range

101–250 employees

Short description

Opsonin Group operates in the pharmaceutical sector, as indicated by its domain (opsonin-pharma.com), but the provided source data does not specify its products, customer segments, geographic markets, or business model.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oral Solid Dose (OSD) Generics (HLAIABAD)

Keywords

• Pharmaceutical products
• Medicine manufacturing
• Drug formulations
• Pharmaceutical distribution
• Healthcare products

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Core offering

Based on the corporate URL (opsonin-pharma.com), Opsonin Group appears to operate in the pharmaceutical sector, likely involved in the manufacturing, distribution, and/or marketing of pharmaceutical products and formulations. The source data does not specify exact products, therapeutic areas, or service offerings, as the live website content was not retrievable.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• Square Pharmaceuticals: Bangladesh's largest pharmaceutical manufacturer producing branded generics across dosage forms; directly comparable in geography, scale, and product mix to Opsonin Group.
• ACI Limited: Bangladeshi conglomerate with a sizable pharma-branded generics business alongside consumer health; comparable in product overlap and Bangladesh-centric distribution.
• Renata Limited: One of the top Bangladeshi pharma manufacturers spanning human generics, animal health, and APIs; provides a direct benchmark for product breadth and regulatory scale.
• Eskayef Pharmaceuticals: Bangladeshi generic drug manufacturer operating across multiple therapeutic areas; competes in the same domestic prescription market as Opsonin.
• Drug International Limited: Bangladeshi pharmaceutical company producing generics and APIs for domestic and export markets; similar product positioning and regulatory profile to Opsonin.
• Beximco Pharmaceuticals: Diversified Bangladeshi generics manufacturer with both domestic market leadership and export operations; comparable across therapeutic categories, manufacturing footprint, and route-to-market.
• Healthcare Pharmaceuticals: Mid-sized Bangladeshi generics manufacturer focused on chronic and specialty therapies; comparable footprint and therapeutic targeting to Opsonin.
• Incepta Pharmaceuticals: Leading Bangladesh-based generic drug manufacturer with a broad OSD-heavy portfolio; competes head-to-head with Opsonin in domestic prescription and OTC channels.

Broad incumbents

• Sun Pharmaceutical Industries: India's largest generics manufacturer with a global distribution footprint and substantial OSD franchise; a much larger incumbent competing with Opsonin in cross-border generic markets.
• Cipla Limited: Indian multinational with a large generics portfolio spanning OSD, inhalers, injectables, and APIs across emerging markets; a broader-scale incumbent operating in adjacent geographies and comparable therapeutic categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks4 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/opsonin-group

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Opsonin Group